Eric Nuermberger

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. pmc Autoluminescent Mycobacterium tuberculosis for rapid, real-time, non-invasive assessment of drug and vaccine efficacy
    Tianyu Zhang
    Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America
    PLoS ONE 7:e29774. 2012
  2. pmc Rapid, serial, non-invasive assessment of drug efficacy in mice with autoluminescent Mycobacterium ulcerans infection
    Tianyu Zhang
    Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America State Key Laboratory of Respiratory Diseases, Center for Infection and Immunity, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, Guangdong, The People s Republic of China
    PLoS Negl Trop Dis 7:e2598. 2013
  3. pmc Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease)
    Annick Chauty
    Centrr de Dépistage et de Traitement de l ulcère de Buruli, Pobè, Benin
    Antimicrob Agents Chemother 51:4029-35. 2007
  4. ncbi Low-dose aerosol model of pneumococcal pneumonia in the mouse: utility for evaluation of antimicrobial efficacy
    Eric Nuermberger
    Division of Infectious Diseases, Department of Medicine, 1503 E Jefferson St, Baltimore, MD 21231, USA
    Int J Antimicrob Agents 26:497-503. 2005
  5. pmc Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model
    Eric Nuermberger
    Center for Tuberculosis Research, Johns Hopkins University, Baltimore, Maryland, USA
    Am J Respir Crit Care Med 172:1452-6. 2005
  6. ncbi Murine models of pneumococcal pneumonia and their applicability to the study of tissue-directed antimicrobials
    Eric Nuermberger
    Division of Infectious Diseases, Department of Medicine, Johns Hopkins University, Baltimore, Maryland 21231, USA
    Pharmacotherapy 25:134S-139S. 2005
  7. pmc Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis
    Eric Nuermberger
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Antimicrob Agents Chemother 50:2621-5. 2006
  8. pmc Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis
    Eric Nuermberger
    Center for Tuberculosis Research, Johns Hopkins University, Baltimore, Maryland, USA
    Antimicrob Agents Chemother 52:1522-4. 2008
  9. ncbi Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis
    Eric L Nuermberger
    Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Am J Respir Crit Care Med 170:1131-4. 2004
  10. ncbi The clinical significance of macrolide-resistant Streptococcus pneumoniae: it's all relative
    Eric Nuermberger
    Center for Tuberculosis Research, Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231 1001, USA
    Clin Infect Dis 38:99-103. 2004

Research Grants

  1. Advancing New Drug Regimens for MDR/XDR TB
    Eric L Nuermberger; Fiscal Year: 2010
  2. Defining Moxifloxacin as a First-line TB Drug
    Eric Nuermberger; Fiscal Year: 2007

Collaborators

Detail Information

Publications44

  1. pmc Autoluminescent Mycobacterium tuberculosis for rapid, real-time, non-invasive assessment of drug and vaccine efficacy
    Tianyu Zhang
    Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America
    PLoS ONE 7:e29774. 2012
    ..Use of this autoluminescent reporter strain has the potential to drastically reduce the time, effort, animals and costs consumed in the evaluation of drug activity in vitro and the in vivo assessment of drug and vaccine efficacy...
  2. pmc Rapid, serial, non-invasive assessment of drug efficacy in mice with autoluminescent Mycobacterium ulcerans infection
    Tianyu Zhang
    Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America State Key Laboratory of Respiratory Diseases, Center for Infection and Immunity, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, Guangdong, The People s Republic of China
    PLoS Negl Trop Dis 7:e2598. 2013
    ..ulcerans in vitro and in vivo. However, the requirement of exogenous substrate limited the utility of such strains, especially for in vivo experiments...
  3. pmc Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease)
    Annick Chauty
    Centrr de Dépistage et de Traitement de l ulcère de Buruli, Pobè, Benin
    Antimicrob Agents Chemother 51:4029-35. 2007
    ..ulcerans disease. Chemotherapy alone was successful in achieving cure in 47% of cases and was particularly effective against ulcers of less than 5 cm in diameter...
  4. ncbi Low-dose aerosol model of pneumococcal pneumonia in the mouse: utility for evaluation of antimicrobial efficacy
    Eric Nuermberger
    Division of Infectious Diseases, Department of Medicine, 1503 E Jefferson St, Baltimore, MD 21231, USA
    Int J Antimicrob Agents 26:497-503. 2005
    ..It may be particularly useful in the evaluation of drugs that concentrate in the alveolar epithelial lining fluid or lung parenchyma...
  5. pmc Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model
    Eric Nuermberger
    Center for Tuberculosis Research, Johns Hopkins University, Baltimore, Maryland, USA
    Am J Respir Crit Care Med 172:1452-6. 2005
    ....
  6. ncbi Murine models of pneumococcal pneumonia and their applicability to the study of tissue-directed antimicrobials
    Eric Nuermberger
    Division of Infectious Diseases, Department of Medicine, Johns Hopkins University, Baltimore, Maryland 21231, USA
    Pharmacotherapy 25:134S-139S. 2005
    ..A promising new, low-dose aerosol model of pneumonia is briefly presented, as is a discussion of the limitations of existing models...
  7. pmc Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis
    Eric Nuermberger
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Antimicrob Agents Chemother 50:2621-5. 2006
    ....
  8. pmc Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis
    Eric Nuermberger
    Center for Tuberculosis Research, Johns Hopkins University, Baltimore, Maryland, USA
    Antimicrob Agents Chemother 52:1522-4. 2008
    ..If applicable to humans, regimens containing this combination may radically shorten the treatment of multidrug-resistant tuberculosis...
  9. ncbi Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis
    Eric L Nuermberger
    Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Am J Respir Crit Care Med 170:1131-4. 2004
    ....
  10. ncbi The clinical significance of macrolide-resistant Streptococcus pneumoniae: it's all relative
    Eric Nuermberger
    Center for Tuberculosis Research, Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231 1001, USA
    Clin Infect Dis 38:99-103. 2004
    ..Areas for further investigation are highlighted...
  11. ncbi Current development and future prospects in chemotherapy of tuberculosis
    Eric L Nuermberger
    Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231 1002, USA
    Respirology 15:764-78. 2010
    ..In the conclusion, we briefly highlight ongoing efforts to discover new compounds and recent advances in alternative drug delivery systems...
  12. pmc Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis
    Rokeya Tasneen
    Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Antimicrob Agents Chemother 55:5485-92. 2011
    ....
  13. pmc Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis
    Rokeya Tasneen
    Center for Tuberculosis Research, Johns Hopkins University, 1550 Orleans Street, Baltimore, MD 21231 1002, USA
    Antimicrob Agents Chemother 52:3664-8. 2008
    ....
  14. pmc In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis
    Deepak Almeida
    Center for Tuberculosis Research, 1550 Orleans Street, Room 105, Baltimore, MD 21231, USA
    Antimicrob Agents Chemother 51:4261-6. 2007
    ..Although this target cannot be achieved clinically with MXF, it might be possible with new fluoroquinolones with more potent activity and/or improved pharmacokinetics...
  15. pmc Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis
    Deepak Almeida
    Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Antimicrob Agents Chemother 53:4178-84. 2009
    ..Finally, a 10-mg/kg dose of INH in mice may best represent the 5-mg/kg dose in humans and decrease the antagonism of INH with RIF-PZA...
  16. ncbi Activity of ketoconazole against Mycobacterium tuberculosis in vitro and in the mouse model
    Sean T Byrne
    Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA
    J Med Microbiol 56:1047-51. 2007
    ..The lowest numbers of bacilli in lungs were found in mice treated with KTC, PZA and RIF. Further investigation is necessary to determine the role of KTC in the treatment of TB...
  17. pmc Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis
    Tetsuyuki Yoshimatsu
    Division of Infectious Diseases, Department of Medicine, Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231 1001, USA
    Antimicrob Agents Chemother 46:1875-9. 2002
    ..e., once-weekly) therapy and should be evaluated in the mouse model of TB...
  18. pmc Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations
    Kelly Dooley
    Divisions of Infectious Diseases, Johns Hopkins University, Baltimore, Maryland 21231, USA
    Antimicrob Agents Chemother 52:4037-42. 2008
    ..Changes consistent with rifapentine autoinduction of metabolism were seen. Adverse reactions in two subjects may have represented rifamycin hypersensitivity syndrome, although some features were atypical...
  19. pmc Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model
    Ian M Rosenthal
    Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America
    PLoS Med 4:e344. 2007
    ..Rifapentine is a long-lived rifamycin derivative currently recommended only in once-weekly continuation-phase regimens. Moxifloxacin is an 8-methoxyfluoroquinolone currently used in second-line regimens...
  20. ncbi Accelerated detection of Mycobacterium tuberculosis genes essential for bacterial survival in guinea pigs, compared with mice
    Sanjay K Jain
    Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Infect Dis 195:1634-42. 2007
    ..However, unlike mice, M. tuberculosis-infected guinea pigs form caseating granulomas, which may simulate human disease more closely...
  21. pmc Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis
    Ian M Rosenthal
    Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Am J Respir Crit Care Med 172:1457-62. 2005
    ..The substitution of moxifloxacin, a new 8-methoxyfluoroquinolone, for isoniazid and an increase in the dose of rifapentine could augment the activity of once-weekly regimens...
  22. pmc Potent twice-weekly rifapentine-containing regimens in murine tuberculosis
    Ian M Rosenthal
    Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Am J Respir Crit Care Med 174:94-101. 2006
    ..Twice-weekly treatment with rifampin, isoniazid, and pyrazinamide may be improved by increasing Mycobacterium tuberculosis exposure to rifamycin by substituting rifapentine for rifampin...
  23. doi Using animal models to develop new treatments for tuberculosis
    Eric Nuermberger
    Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
    Semin Respir Crit Care Med 29:542-51. 2008
    ..This chapter reviews some of the important considerations when selecting an animal model and presents a model for the sequential evaluation of a new compound with promising antituberculosis activity...
  24. ncbi Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis
    Eric L Nuermberger
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Am J Respir Crit Care Med 169:421-6. 2004
    ..The findings suggest that this regimen has the potential to substantially shorten the duration of therapy needed to cure human tuberculosis...
  25. pmc Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?
    Ian M Rosenthal
    Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Am J Respir Crit Care Med 178:989-93. 2008
    ..This study was designed to more precisely evaluate the contribution of moxifloxacin and isoniazid to rifapentine-based regimens...
  26. doi Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis
    Kathy N Williams
    Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Am J Respir Crit Care Med 180:371-6. 2009
    ..We recently reported strong bactericidal activity of the oxazolidinone PNU-100480 and its ability to increase the initial bactericidal effect of various combinations of first-line tuberculosis drugs and moxifloxacin in a murine model...
  27. pmc Using bioluminescence to monitor treatment response in real time in mice with Mycobacterium ulcerans infection
    Tianyu Zhang
    Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Antimicrob Agents Chemother 55:56-61. 2011
    ..These results indicate the potential of bioluminescence as a real-time surrogate marker for viable bacteria in mouse footpads to accelerate the identification of new treatments for Buruli ulcer...
  28. pmc PA-824 exhibits time-dependent activity in a murine model of tuberculosis
    Zahoor Ahmad
    Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21231 1002, USA
    Antimicrob Agents Chemother 55:239-45. 2011
    ..T(>MIC), in conjunction with AUC/MIC, is the parameter on which dose optimization of PA-824 should be based...
  29. ncbi Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes
    John S Francis
    Division of Infectious Diseases, Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Clin Infect Dis 40:100-7. 2005
    ..During a 2-month period in the winter of 2003-2004, four healthy adults presented to 1 of 2 Baltimore hospitals with severe necrotizing MRSA pneumonia in the absence of typical risk factors for MRSA infection...
  30. ncbi Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis
    Susan E Dorman
    Johns Hopkins University Center for Tuberculosis Research, Baltimore, Maryland 21231, USA
    Am J Respir Crit Care Med 180:273-80. 2009
    ..Moxifloxacin has potent activity against Mycobacterium tuberculosis in vitro and in a mouse model of antituberculosis (TB) chemotherapy, but data regarding its activity in humans are limited...
  31. pmc Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice
    Ming Zhang
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, 1501 Orleans Street, Baltimore, MD 21231, USA
    Am J Respir Crit Care Med 183:1254-61. 2011
    ..Daily rifapentine plus isoniazid-pyrazinamide in mice infected with Mycobacterium tuberculosis produces cure in 3 months. Whether cure corresponds to latent infection contained by host immunity or true tissue sterilization is unknown...
  32. ncbi Polymerized human Hb use in acute chest syndrome: a case report
    Sophie Lanzkron
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Transfusion 42:1422-7. 2002
    ..Transfusion therapy has been shown to significantly increase oxygenation in patients with ACS and RBC exchange is considered the standard of care in patients at high risk of respiratory failure...
  33. pmc Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections
    Zahoor Ahmad
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Antimicrob Agents Chemother 55:1527-32. 2011
    ..Clinical studies are warranted to investigate the sterilizing activity and tolerability of higher doses of pyrazinamide in combination tuberculosis regimens...
  34. pmc Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig
    Zahoor Ahmad
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    J Antimicrob Chemother 65:729-34. 2010
    ..In this study, we sought to compare the sterilizing activity of human-equivalent doses of the 'Denver regimen' against acute tuberculosis (TB) infection in the standard mouse model and in the guinea pig...
  35. pmc Dormancy phenotype displayed by extracellular Mycobacterium tuberculosis within artificial granulomas in mice
    Petros C Karakousis
    Dept of Medicine, Center for Tuberculosis Research, Johns Hopkins University School of Medicine, 1503 E Jefferson St, Rm 112, Baltimore, MD 21231, USA
    J Exp Med 200:647-57. 2004
    ..Interestingly, the dormancy phenotype of extracellular M. tuberculosis within host granulomas appears to be immune mediated and interferon-gamma dependent...
  36. pmc Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection
    Tianyu Zhang
    Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Am J Respir Crit Care Med 180:1151-7. 2009
    ....
  37. ncbi Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig
    Zahoor Ahmad
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21289, USA
    J Infect Dis 200:1136-43. 2009
    ..This reduction in activity was not associated with the emergence of isoniazid-resistant mutant strains but, rather, with the selection of phenotypically tolerant "persisters."..
  38. pmc Role of the dosR-dosS two-component regulatory system in Mycobacterium tuberculosis virulence in three animal models
    Paul J Converse
    Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Infect Immun 77:1230-7. 2009
    ..Our analyses reveal that the dosR and dosS genes are required for full virulence and that there may be differences in the patterns of attenuation of this mutant between the animal models studied...
  39. pmc Noninvasive pulmonary [18F]-2-fluoro-deoxy-D-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment
    Stephanie L Davis
    Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Antimicrob Agents Chemother 53:4879-84. 2009
    ..By reducing animal numbers, these biomarkers will allow cost-effective studies of more expensive animal models of TB. Validated markers may also be useful as "point-of-care" methods to monitor TB treatment in humans...
  40. pmc Activity of the fluoroquinolone DC-159a in the initial and continuation phases of treatment of murine tuberculosis
    Zahoor Ahmad
    Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Antimicrob Agents Chemother 55:1781-3. 2011
    ..These results warrant further preclinical evaluation of DC-159a in selected drug combinations against drug-susceptible and fluoroquinolone-resistant tuberculosis...
  41. ncbi Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat
    Nicola Zetola
    Department of Medicine, Johns Hopkins University, Baltimore, MD 21231 1001, USA
    Lancet Infect Dis 5:275-86. 2005
    ....
  42. ncbi Significance of macrolide resistance in Streptococcus pneumoniae
    Eric L Nuermberger
    J Antimicrob Chemother 52:524-5; author reply 525. 2003
  43. ncbi Antibiotic resistance in Streptococcus pneumoniae: what does the future hold?
    Eric L Nuermberger
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231 1001, USA
    Clin Infect Dis 38:S363-71. 2004
    ..Much investigation is still needed to better ascertain how maintenance of DRSP strains in the community at large is influenced by each factor and affected by current interventions that are based on these factors...
  44. pmc Evaluation of new antituberculosis drugs in mouse models
    G R Davies
    Antimicrob Agents Chemother 51:403; author reply 403-4. 2007

Research Grants3

  1. Advancing New Drug Regimens for MDR/XDR TB
    Eric L Nuermberger; Fiscal Year: 2010
    ..The goal is to identify potent drug combinations that are likely to be safe and effective and that could be subsequently tested in human clinical trials. ..
  2. Defining Moxifloxacin as a First-line TB Drug
    Eric Nuermberger; Fiscal Year: 2007
    ..Relevance: Results of these studies will help to define optimal treatment regimens for TB that can be used to design new clinical trials or, in some cases, directly applied to clinical practice. ..